Equillium clears Phase 1 trial for EQ504; dosing to begin November

Equillium received Human Research Ethics Committee approval and Therapeutic Goods Administration clearance in Australia to initiate a Phase 1 clinical trial of EQ504, with dosing of healthy participants expected to begin by early November 2026. This represents regulatory clearance to move a drug candidate into human testing, validating the path forward for the compound, though Phase 1 trials are early-stage studies with inherent execution risk and no guarantee of efficacy outcomes.

Equillium got approval from Australian regulators to start testing its experimental drug EQ504 in healthy people starting in November. This is an early-stage test to check if the drug is safe.